Western University Launches Global Initiative for HIV Cure Access

At Western University in Canada, an innovative initiative aims to transform access to HIV treatment and potential cures for millions around the globe. Led by Eric Arts, Canada Research Chair in HIV Pathogenesis and Viral Control, the project, named IMMUNEQUITY, seeks to address the stark inequities in healthcare access that continue to affect individuals living with HIV.

After significant advancements in HIV treatment over the past three decades, the benefits of medical breakthroughs remain unevenly distributed. Arts emphasizes the urgency of this matter, stating, “Where you live still determines whether you benefit from medical breakthroughs.” He highlights that while antiretroviral therapy (ART) has turned HIV into a manageable condition, many in sub-Saharan Africa face delays in accessing these advancements, often relying on unstable international aid.

Currently, approximately 40 million people worldwide live with HIV, and many depend on daily medication. While there is a technical cure involving hematopoietic stem cell transplantation (HSCT), the procedure is complex, risky, and costly—averaging over $350,000 per patient. Such challenges make scaling the treatment impractical in low- and middle-income countries, where the need is greatest.

Revolutionizing HIV Treatment Development

The IMMUNEQUITY initiative is a collaboration involving professors from various disciplines, including medical biophysics, engineering, and law, alongside Ugandan partners at the Joint Clinical Research Centre (JCRC) and Makerere University. Their collaborative effort aims to rethink the design of HIV cures, integrating affordability, manufacturability, and equitable access from the outset.

According to Peter Zandstra, Canada Research Chair in Stem Cell Engineering, the initiative presents a compelling opportunity: “If we can solve the manufacturing and distribution challenges alongside the biology, the impact could extend well beyond Canada to millions of people worldwide.”

At the heart of this initiative is a strategy known as “kick and kill,” which seeks to activate dormant HIV-infected cells and subsequently target them for elimination. Instead of relying on toxic chemotherapies, the team focuses on biologics—immunotherapies designed to specifically target HIV-infected cells. This approach not only promises to be more effective but also aims to reduce costs significantly for low-income countries.

Community Engagement and Local Collaboration

The Pathogen Research Centre, a $44 million facility currently under construction at Western Research Parks, will play a vital role in supporting the IMMUNEQUITY initiative. The project emphasizes that cost considerations must be integrated into the research design from the very beginning.

“New biotherapeutics will not succeed if they are developed in isolation from the realities of low-resource health systems,” said Maria Drangova, one of the project’s leading researchers. “They must be designed in parallel with scalable manufacturing and reliable delivery infrastructure.”

By engaging with communities living with HIV in Canada and Uganda, the initiative ensures that legal, social, and ethical considerations are integral to its development. Bassem Awad, faculty director of the Western Intellectual Property and Innovation Legal Clinic, will spearhead the project’s intellectual property strategy to eliminate potential barriers to treatment access.

The collaboration draws on a long-standing partnership between Eric Arts and Dr. Cissy Kityo Mutuluuza, a prominent Ugandan physician and researcher. This partnership, formalized in March 2022, aims to co-develop technologies that are not only effective but also contextually relevant to the communities they serve.

With more than 70 percent of individuals living with HIV residing in low- and middle-income countries, the initiative’s implications are significant. In Uganda, the annual cost of HIV treatment using generic ART is approximately US$1,000, while in wealthier nations, it can exceed $30,000.

The objective of IMMUNEQUITY extends beyond merely curing HIV; it aims to pioneer a model of biomedical innovation that bridges the gap between discovery and equitable access. If successful, the framework developed through this initiative could be applied to combat other infectious diseases and chronic conditions in resource-limited settings.

As Eric Arts aptly summarizes, “The best cure in the world is meaningless if it cannot be produced at a large scale and affordable cost in resource-limited settings.” Through IMMUNEQUITY, the hope is to create a future where lifesaving treatments are accessible to all, not just the privileged few.